United States - English - NLM (National Library of Medicine)

physicians total care, inc. - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - salmeterol xinafoate 50 ug - advair diskus is indicated for the treatment of asthma in patients aged 4 years and older. long-acting beta2 -adrenergic agonists (labas), such as salmeterol, one of the active ingredients in advair diskus, increase the risk of asthma-related death. available data from controlled clinical trials suggest that labas increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see warnings and precautions (5.1)] .therefore, when treating patients with asthma, physicians should only prescribe advair diskus for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid, or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a laba. once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue advair diskus) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, s

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - salmeterol 50 ug - serevent diskus is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with a long-term asthma control medication, such as an inhaled corticosteroid, in patients aged 4 years and older with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma. laba, such as salmeterol, the active ingredient in serevent diskus, increase the risk of asthma-related death [see warnings and precautions (5.1)] . use of serevent diskus for the treatment of asthma without concomitant use of a long-term asthma control medication, such as an inhaled corticosteroid, is contraindicated [see contraindications (4)] . use serevent diskus only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid. once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue sere

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - salmeterol 50 ug - serevent diskus is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with an ics in patients aged 4 years and older with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma. laba, such as salmeterol, the active ingredient in serevent diskus, as monotherapy (without ics) increase the risk of asthma-related death [see warnings and precautions (5.1)] . use of serevent diskus for the treatment of asthma without concomitant use of an ics is contraindicated [see contraindications (4)] . use serevent diskus only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on an ics. do not use serevent diskus for patients whose asthma is adequately controlled on low- or medium-dose ics. pediatric and adolescent patients available data from controlled clinical trials suggest that laba as monotherapy increase the risk of asthma-related hospitalization in pediatric and adolescent pati

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - salmeterol xinafoate - pressurised inhalation - 25microgram/1dose

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - salmeterol xinafoate - pressurised inhalation - 25microgram/1dose

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - salmeterol xinafoate - inhalation powder - 50microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - salmeterol xinafoate - pressurised inhalation - 25microgram/1dose

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - salmeterol xinafoate - pressurised inhalation - 25microgram/1dose

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sandoz gmbh - salmeterol (xinafoato) - salmeterol (xinafoato)....50.00 mcg / fluticasona propionato....500.00 mcg

Kenya - English - Pharmacy and Poisons Board

cipla ltd cipla house, peninsula business park, ganpatrao - salmeterol as salmeterol xinafoate ph. eur &… - inhalation powder - salmeterol as salmeterol xinafoate ph. eur 25… - salmeterol and fluticasone